Studying Long COVID in Drug Development

As the initial COVID-19 pandemic begins to resolve in the form of vaccines and treatment pathways, research into the long-term effects of COVID is building. In response, in December, Congress provided $1.15 billion in funding over four years for NIH to support research into the prolonged health consequences of SARS-CoV-2 infection. This roundtable of experts from various stakeholder groups will discuss the current research into long-haul COVID, or PASC; disparate theories of causes; challenges in research and diagnosis, as well as PASC potential in drug development.

Can Synthetic Control Arms Address Regulator and HTA Evidence Requirements?

***Tuesday, March 30, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST*** How can real-world data enrich our understanding of patient care and outcomes? A panel of experts will share perspectives on the right role and impact for external control arms on trials, approval and access, including ways RWE can help overcome approval and access barriers. ***On demand available after final airing until Mar. 30, 2022***